Affordable Access

deepdyve-link
Publisher Website

Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings.

Authors
  • Park, Susanna S1
  • Bauer, Gerhard2
  • Abedi, Mehrdad3
  • Pontow, Suzanne2
  • Panorgias, Athanasios1
  • Jonnal, Ravi1
  • Zawadzki, Robert J1
  • Werner, John S1
  • Nolta, Jan2
  • 1 Department of Ophthalmology and Vision Science, University of California-Davis Eye Center, Sacramento, California, United States. , (United States)
  • 2 Institute for Regenerative Cures, University of California-Davis School of Medicine, Sacramento, California, United States. , (United States)
  • 3 Division of Hematology and Oncology, University of California-Davis Cancer Center, Sacramento, California, United States. , (United States)
Type
Published Article
Journal
Investigative ophthalmology & visual science
Publication Date
Dec 09, 2014
Volume
56
Issue
1
Pages
81–89
Identifiers
DOI: 10.1167/iovs.14-15415
PMID: 25491299
Source
Medline
Keywords
License
Unknown

Abstract

Intravitreal autologous BM CD34+ cell therapy appears feasible and well tolerated in eyes with ischemic or degenerative retinal conditions and merits further exploration. (ClinicalTrials.gov number, NCT01736059.).

Report this publication

Statistics

Seen <100 times